
Targeting Amino Acid Metabolic Vulnerabilities in Myeloid …
2021年5月20日 · Overexpression of AMD1, ODC1, and SMS in AML is regulated by the extended signaling network of the MYC oncoprotein, which is amplified in over 90% of AML patients (92–94). Indeed, disruption of MYC signaling in the human AML cell lines MOLM-13, HL60, THP1, and KG1a leads to a marked downregulation in AMD1expression ( 95 ).
Metabolism in stem cell–driven leukemia: parallels between ...
2023年5月25日 · Increased levels of amino acid transporter LAT1 have been shown to be critical for ALL and AML. 67, 148 LAT1 transports multiple amino acids, including glutamine, into the cell . LAT1 is a heterodimeric protein that comprises SLC7A5 (CD98), which also functions as a vasculature-integrin–binding glycoprotein, and SLC3A2.
Nature Reviews | 靶向肿瘤代谢的精准治疗 - 知乎 - 知乎专栏
与v-9302的抗肿瘤活性及其对l型氨基酸转运体1(lat1)依赖的中性氨基酸转运的抑制一致,lat1在kras突变的结直肠癌(crc)模型中被发现对肿瘤的发生至关重要。
L-type amino acid transporter 1 as a target for inflammatory disease ...
2022年1月1日 · In this review, we aimed to introduce the function of amino acids and their transporters in immune cells, with emphasis on L-type amino acid transporter 1 (LAT1), a transporter of large amino acids. Additionally, we discuss the potential of targeting LAT1 for immune disease treatment and cancer immune therapy. 2. LAT1 and T cell.
JCI - Clinical development of metabolic inhibitors for oncology
2022年1月4日 · LAT1 preferentially transports branched-chain amino acids (valine, leucine, isoleucine) and aromatic amino acids (tryptophan, tyrosine). LAT1 is overexpressed in many cancer cells, which consume these amino acids to sustain proliferation.
CD98 signals controlling tumorigenesis - ScienceDirect
2016年12月1日 · CD98 light chains LAT-1 and LAT-2 can activate mTOR. CD98hc interacts with β1 and β3 integrins, mediating cell survival, proliferation and migration. The CD98 heterocomplex activates the PI3 K/Akt and MAPK signaling pathways. LAT-1 inhibitors are being tested in pre-clinical studies. Various approaches to blocking CD98hc are being trialed.
Metabolic Signaling to the Nucleus in Cancer - Cell Press
2018年8月2日 · LAT1 expression is increased by activity of the methyltransferase EZH2, allowing for sustained methionine uptake and SAM production for histone methylation (Dann et al., 2015). (C) In breast cancer cells, high levels of O-GlcNAcylation supported by glucose use in the HBP result in suppressed α-KG levels, which reduces prolyl hydroxylase ...
IMPDH inhibition activates TLR‐VCAM1 pathway and suppresses …
2022年12月1日 · Although VCAM1 expression is low in most primary AML cells and AML cell lines, IMPDH inhibition induced Vcam1 upregulation in MLL‐AF9‐AML cells. Moreover, our functional analyses revealed the critical role of Vcam1 to regulate cell–cell interaction among AML cells, which prevents their leukemic proliferation.
Nature Medicine研究 (IF87): AML异质性及药物反应预测 - 知乎
2022年10月9日 · 急性髓性白血病 (acute myeloid leukemia,AML)是一种破坏性疾病,其特征是患者间和患者中广泛异质性。预后不佳的原因是首次化疗耐药和获得缓解的患者高复发率,这凸显了普通化疗对治疗大多数AML存在不足。
29th EHA Congress Travel Award 受賞レポート 栁谷 稜
2025年1月22日 · Among amino acids transported via LAT1, sulfur-containing amino acids were annotated as key regulators of ANKL proliferation, and ANKL cells in environment with lower concentration of them decreased cell growth activity and …